Zinzino

Zinzino is a Swedish health and wellness network marketing company founded in 2005 by Norwegian entrepreneurs Hilde and Ørjan Sæle. The business began as the exclusive Northern European sales organization for Belgian-French coffee company Rombouts, initially operating in Norway and Sweden before expanding across Scandinavia. Zinzino later shifted decisively toward nutrition and wellness. In 2012, the company partnered with Norwegian research company BioActive Foods to introduce its Balance product line, including BalanceOil and a dried-blood-spot fatty-acid test. Zinzino acquired the remaining 90% of BioActive Foods in December 2014, making it a wholly owned subsidiary. The company's Class B shares began trading on Nasdaq First North in December 2014 under the ticker ZZ B.

Zinzino's current business centers on what it describes as test-based nutrition. Its flagship BalanceTest analyzes fatty acids from a dried blood sample, while BalanceOil+ combines omega-3 fatty acids with polyphenols from olive oil. The product line has expanded to include the Gut Health Test, Vitamin D Test, HbA1c Test, BalanceOil+ Premium, vegan omega-3 products, nutritional supplements, functional foods and skin-care products. The company states that more than 1.7 million BalanceTests have been completed and that its products are sold in more than 100 markets on five continents through more than 40,000 Independent Partners.

Zinzino operates through a multilevel direct-selling compensation system. Independent Partners earn commissions on retail customer sales and can also receive Team Commissions generated by distributors they recruit and by subsequent distributors within their organizations. The company's current Partner Rewards Program includes customer-sales commissions, recurring income, Fast Start incentives, advancement through 17 achievement ranks, incentive travel and other rewards. New Partners can join without purchasing a product package, although Zinzino also sells optional Partner Kits. In the United States, current kits range from a Basic Kit to larger Advanced and Ultimate packages, with retail values exceeding $3,000 for some packages. Current company materials state that a Partner earns 10% beginning with the first qualifying customer sale.

Zinzino has grown substantially through both organic expansion and acquisitions. The company reported SEK 3.34 billion in 2025 revenue, up 51% from SEK 2.21 billion in 2024, with EBITDA of SEK 443.4 million. During 2025 it acquired the assets of U.S. direct seller Zurvita following Zurvita's Chapter 11 proceedings for approximately SEK 127 million, including its distributor database, inventory and Zeal brand rights. It also acquired the assets of Valentus Global for approximately SEK 19.6 million. Earlier acquisitions included VMA Life, Enhanzz, Xelliss and portions of the Cleanthi olive-oil operation.

The acquisition strategy continued in 2026. Effective January 1, Zinzino acquired the assets of Mexican direct-selling company Sanki for a fixed purchase price of $8 million. On January 26, 2026, Zinzino completed a much larger transaction with It Works!, acquiring the operating assets of its U.S. business and its international operating subsidiaries for a fixed $30 million in Zinzino shares, with an estimated additional $4 million contingent on future sales. Zinzino reported SEK 922.1 million in first-quarter 2026 revenue, a 27% increase from the same period in 2025, and EBITDA of SEK 142.3 million.

Zinzino has also faced scrutiny over health and earnings claims made by members of its salesforce. In 2021, the Direct Selling Self-Regulatory Council reviewed social-media claims suggesting Zinzino products could provide protection from COVID-19 and company language implying that Partners could obtain full-time income or wealth. Zinzino removed or agreed to revise the claims, and DSSRC closed the inquiry in June 2021. DSSRC stated that Zinzino did not dispute that its products were not intended to diagnose, treat, cure or prevent disease.

A second DSSRC inquiry was completed in February 2025. That case examined twelve earnings claims involving statements such as financial freedom, full-time income and specific monthly income levels, along with product claims involving cholesterol, immune function, brain function and inflammation. Zinzino did not attempt to substantiate the challenged claims and instead contacted the distributors responsible for them. Fourteen posts were removed and one was modified. DSSRC administratively closed the case after finding that Zinzino had made good-faith efforts to remove or correct the claims.

Zinzino remains a publicly traded and rapidly expanding direct-selling company in 2026.

Dag Bergheim Pettersen, Chief Executive Officer

Hilde Sæle, Co-Founder

Ørjan Sæle, Co-Founder

Fredrik Nielsen, Chief Financial Officer

Gabriele Helmer, Chief Marketing Officer

Dr. Colin Robertson, Chief Product Officer